Medidata Secures a Leader Position in Everest Group's PEAK Matrix® Assessment for eCOA, Driving the New Patient Experience Forward

Core Insights - Medidata has been recognized as a Leader in Everest Group's Life Sciences Electronic Clinical Outcome Assessment (eCOA) Products PEAK Matrix® Assessment 2025, highlighting its success in delivering impactful solutions in the life sciences industry [1][4] - The company has maintained its leadership in the eCOA market for over a decade, with its solutions foundational to thousands of global studies across various indications [2][3] - Medidata eCOA significantly reduces study design and startup timelines, with a reduction of up to six weeks compared to the industry standard of 12 or more weeks [2] Company Achievements - Medidata's eCOA has been enhanced through a partnership with Cogstate, focusing on reducing rater burden and improving signal detection in Central Nervous System (CNS) trials [2] - The company has received consistent recognition from Everest Group in 2023 and 2024 for its Decentralized Clinical Trials, reinforcing its leadership in the clinical trial space [4] - Medidata Rave EDC and Medidata Rave CTMS have also been acknowledged, showcasing the company's commitment to improving clinical trial operations and accelerating the delivery of therapies [4] Industry Impact - Medidata has powered over 36,000 trials and 11 million patients, offering industry-leading expertise and one of the largest clinical trial data sets [6] - The company serves approximately 2,300 customers, with more than 1 million registered users relying on its end-to-end platform to enhance patient experiences and expedite clinical breakthroughs [6]